These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

65 related items for PubMed ID: 9439979

  • 1. Effects of interferon-alpha therapy on lymphocyte subpopulations in patients with chronic myeloid leukemia.
    Sacchi S, Cortes J, Kantarjian H, Talpaz M.
    Hematopathol Mol Hematol; ; 11(1):41-7. PubMed ID: 9439979
    [Abstract] [Full Text] [Related]

  • 2. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G, GIMEMA Working Party on Chronic Myeloid Leukemia.
    Clin Cancer Res; 2006 May 15; 12(10):3037-42. PubMed ID: 16707599
    [Abstract] [Full Text] [Related]

  • 3. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.
    Reuben JM, Lee BN, Johnson H, Fritsche H, Kantarjian HM, Talpaz M.
    Clin Cancer Res; 2000 May 15; 6(5):1671-7. PubMed ID: 10815885
    [Abstract] [Full Text] [Related]

  • 4. [Treatment with lymphoblastoid alpha interferon in patients with chronic myeloid leukemia refractory to recombinant interferon alpha 2].
    Steegmann JL, Granados E, Vázquez L, de la Cámara R, Peñarrubia MJ, Fernández-Contreras E, Quiroga JA, Fernández Rañada JM.
    Sangre (Barc); 1998 Oct 15; 43(5):443-6. PubMed ID: 9868341
    [Abstract] [Full Text] [Related]

  • 5. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K, Minami S, Ueda T, Nishimura M, Tsubaki K, Takemoto Y, Takeshita A, Sao H, Kageyama S, Ueda R, Ohno R.
    Int J Hematol; 2000 Aug 15; 72(2):229-36. PubMed ID: 11039674
    [Abstract] [Full Text] [Related]

  • 6. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia.
    Aswald JM, Lipton JH, Aswald S, Messner HA.
    Cytokines Cell Mol Ther; 2002 Aug 15; 7(4):143-9. PubMed ID: 14660054
    [Abstract] [Full Text] [Related]

  • 7. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J, Talpaz M, O'Brien S, Giles F, Beth Rios M, Shan J, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Kantarjian H.
    Cancer; 2003 Sep 15; 98(6):1105-13. PubMed ID: 12973833
    [Abstract] [Full Text] [Related]

  • 8. [Molecular biology follow-up of interferon therapy in patients with chronic myeloid leukemia].
    Iványi JL, Marton E, Kereskai L, Kiss Z, Pajor L.
    Orv Hetil; 2000 Nov 19; 141(47):2527-33. PubMed ID: 11143285
    [Abstract] [Full Text] [Related]

  • 9. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H, O'Brien S, Cortes J, Shan J, Giles F, Garcia-Manero G, Verstovsek S, Faderl S, Rios MB, Talpaz M.
    Cancer; 2003 Oct 01; 98(7):1430-7. PubMed ID: 14508830
    [Abstract] [Full Text] [Related]

  • 10. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.
    Steegmann JL, Moreno G, Aláez C, Osorio S, Granda A, de la Cámara R, Arranz E, Reino FG, Salvanés FR, Fernández-Rañada JM, Muñoz C.
    Haematologica; 2003 Jul 01; 88(7):762-8. PubMed ID: 12857554
    [Abstract] [Full Text] [Related]

  • 11. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE.
    Clin Cancer Res; 2002 Jul 01; 8(7):2177-87. PubMed ID: 12114418
    [Abstract] [Full Text] [Related]

  • 12. Therapy-related changes of CD20+ and CD45RO+ lymphocyte subsets in chronic myeloid leukemia (CML): an immunohistochemical and morphometric study on sequential trephine biopsies of the bone marrow.
    Thiele J, Kvasnicka HM, Schmitt-Graeff A, Cvetanovska G, Blum N, Schaefer HE.
    Mod Pathol; 2000 Aug 01; 13(8):888-96. PubMed ID: 10955456
    [Abstract] [Full Text] [Related]

  • 13. Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon.
    Cervantes F, Sureda A, Hernández-Boluda JC, Martino R, Brunet S, Borrego D, Antich JL, Montserrat E.
    Haematologica; 2001 Dec 01; 86(12):1281-6. PubMed ID: 11726320
    [Abstract] [Full Text] [Related]

  • 14. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses.
    Peñarrubia MJ, Odriozola J, González C, Massagué I, Miguel A, González San Miguel JD, Pérez Encinas M, Lavilla E, Giraldo MP, Casado LF, Ferrer S, Steegmann JL, Spanish Group on IFN and CML.
    Ann Hematol; 2003 Dec 01; 82(12):750-8. PubMed ID: 14517691
    [Abstract] [Full Text] [Related]

  • 15. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
    Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado E, Jiménez-Zamudio L, Moreno-Lafont M, García-Latorre E, Ramírez-Sanjuan E, Montiel-Cervantes L, Tripp-Villanueva F, García-León LD, Ayala-Sánchez M, Rosas-Cabral A, Aviña-Zubieta JA, Galindo-Rodríguez G, Vadillo-Buenfil M, Salazar-Exaire D.
    Ann Hematol; 2004 May 01; 83(5):295-301. PubMed ID: 15060749
    [Abstract] [Full Text] [Related]

  • 16. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
    Li YF, Deng ZK, Xuan HB, Zhu JB, Ding BH, Liu XN, Chen BA.
    Chin Med J (Engl); 2009 Jun 20; 122(12):1413-7. PubMed ID: 19567163
    [Abstract] [Full Text] [Related]

  • 17. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH.
    Biol Blood Marrow Transplant; 2004 Mar 20; 10(3):204-12. PubMed ID: 14993886
    [Abstract] [Full Text] [Related]

  • 18. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.
    Clin Cancer Res; 2005 May 01; 11(9):3425-32. PubMed ID: 15867244
    [Abstract] [Full Text] [Related]

  • 19. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation.
    Steegmann JL, Casado LF, Tomás JF, Sanz-Rodríguez C, Granados E, de la Cámara R, Alegre A, Vázquez L, Ferro MT, Figuera A, Arranz R, Fernández-Rañada JM.
    Bone Marrow Transplant; 1999 Mar 01; 23(5):483-8. PubMed ID: 10100563
    [Abstract] [Full Text] [Related]

  • 20. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S, Giles F, Talpaz M, Cortes J, Rios MB, Shan J, Thomas D, Andreeff M, Kornblau S, Faderl S, Garcia-Manero G, White K, Mallard S, Freireich E, Kantarjian HM.
    Cancer; 2003 Sep 01; 98(5):888-93. PubMed ID: 12942553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.